Welcome to our dedicated page for Elutia SEC filings (Ticker: ELUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elutia Inc. (ELUT) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret complex documents. Elutia is a regenerative medicine company that develops drug-eluting biomatrix products, and its filings provide detailed insight into how this business is structured, financed and governed.
Key documents for ELUT include Form 10-K annual reports and Form 10-Q quarterly reports, which discuss Elutia’s drug-eluting biomatrix platform, segment information such as historical Device Protection, Women’s Health and Cardiovascular activities, risk factors, and management’s analysis of operating performance. These reports also describe the company’s focus on NXT-41 and NXT-41x in plastic and reconstructive surgery and summarize prior divestitures, including the Orthobiologics business and the CIED/BioEnvelope business.
Elutia files frequent Form 8-K current reports to document material events. Recent 8-Ks have covered the agreement and closing of the sale of its CIED business to Boston Scientific and Cardiac Pacemakers Inc., amendments to its credit facility with SWK Funding LLC, the use of sale proceeds to repay that facility, board changes, and a Nasdaq notice regarding minimum bid price compliance. These filings also attach press releases with financial results and transaction details, giving additional context on cash flows, debt reduction and strategic focus.
Investors can also use this page to access proxy and governance filings when available, as well as any Form 4 insider transaction reports that disclose trades by directors and officers. Stock Titan’s AI features summarize lengthy filings, highlight sections on regulatory risk, litigation related to products such as FiberCel, royalty and revenue interest obligations, and explain how transactions like the BioEnvelope sale affect Elutia’s balance sheet and future plans.
By reviewing ELUT’s SEC filings alongside AI-generated explanations, users can quickly understand the regulatory history, capital structure changes and strategic decisions that shape Elutia’s drug-eluting biomatrix business.
ELUTIA INC. director Guido J. Neels exercised restricted stock units that vested into 6,250 shares of Class A Common Stock at a price of $0.00 per share. These shares came from a grant of 25,000 restricted stock units that vests in four equal installments. Following this vesting and conversion, Neels directly owns 125,000 shares of Class A Common Stock.
Elutia Inc. is reshaping its business around drug‑eluting biomatrix products for reconstructive surgery after selling noncore segments. In October 2025 it sold substantially all assets of its cardiac implantable electronic device business to Boston Scientific and an affiliate for up to $88.0 million in cash, recognizing a $76.1 million gain. Earlier, it divested its Orthobiologics segment for $14.6 million plus up to $20.0 million of potential earn‑outs and has already recorded gains of $6.2 million. The company is now centered on SimpliDerm and cardiovascular patches while developing next‑generation programs NXT‑41 and NXT‑41x, which combine biologic scaffolds with local antibiotic delivery and are targeted for FDA clearance in the second half of 2026 and by mid‑2027, respectively.
Elutia remains loss‑making, with losses from continuing operations of $26.9 million in 2025 and $30.7 million in 2024, and depends on growing its Women’s Health and Cardiovascular businesses and successfully launching NXT‑41x. It also faces significant product‑liability exposure from recalls of FiberCel and viable bone matrix products, with an estimated contingent liability of $11.2 million, including $6.8 million for FiberCel where insurance coverage is exhausted. As of March 4, 2026, Elutia had 42,784,848 Class A shares outstanding and 26 employees, and is emphasizing a lean, integrated R&D, manufacturing and commercialization model to support its focused growth strategy.
Elutia Inc.’s Chief Scientific Officer, Michelle LeRoux Williams, increased her direct equity stake through restricted stock unit vesting. On March 10, 2026, 12,500 restricted stock units converted into an equal number of Class A Common shares, reflecting previously granted equity compensation.
To cover tax withholding on this vesting, 4,613 shares of Class A Common Stock were withheld by the company at a price of $1.09 per share, leaving a net 7,887 newly held shares. Following these routine compensation-related transactions, she directly owns 109,821 shares of Class A Common Stock and 37,500 restricted stock units, each representing a contingent right to receive one share.
Elutia Inc. President and CEO C. Randal Mills reported compensation-related stock activity. On 2026-03-10, restricted stock units vested, resulting in the acquisition of 27,084 shares of Class A Common Stock, with each unit representing one share. The issuer withheld 11,100 shares at $1.09 per share to cover tax obligations associated with the vesting. Following these transactions, Mills directly holds 409,406 shares of Class A Common Stock, indicating a routine equity award vesting and related tax withholding rather than an open-market trade.
Elutia Inc.’s chief financial officer Matthew Ferguson reported routine equity compensation activity. On March 10, 2026, 12,500 restricted stock units vested and were exercised into 12,500 shares of Class A Common Stock. To cover tax obligations on this vesting, 5,123 shares were withheld by the company at a price of $1.09 per share, leaving a net increase of 7,377 shares. After these transactions, Ferguson directly owns 472,067 shares of Class A Common Stock. The vested RSUs are part of a 150,000-unit grant awarded on January 31, 2024, which vests in scheduled installments through December 10, 2026.
Elutia Inc. reported fourth-quarter and full-year 2025 results and highlighted a major strategic shift. Net sales from continuing operations were $3.3M in Q4 2025, up from $2.8M, but full-year 2025 sales declined to $12.3M from $14.5M.
Loss from continuing operations narrowed sharply to $15.9M in 2025 from $45.3M in 2024 as operating expenses fell. Thanks largely to a $88M BioEnvelope divestiture, income from discontinued operations was $69.3M, driving full-year net income of $53.4M versus a $53.9M loss in 2024.
Year-end cash and escrowed proceeds totaled $44.4M, with long-term debt eliminated and stockholders’ equity improving from a deficit of $(46.3M) to positive $27.7M. Elutia submitted its base biologic matrix NXT-41 to the FDA and expects NXT-41 clearance in the second half of 2026 and full NXT-41x clearance in the first half of 2027.
Elutia Inc. adopted a new 2026 Inducement Award Plan to grant equity-based incentives to people who are newly hired by the company or its subsidiaries. The plan is intended to help attract, retain and motivate employees who are expected to make important contributions.
The Inducement Plan allows grants of stock options (excluding incentive stock options), stock appreciation rights, restricted stock, restricted stock units, other stock- or cash-based awards, and dividend equivalents, covering up to 2,000,000 shares of Class A common stock. Awards may only be made as material inducements to employment under Nasdaq Listing Rule 5635(c)(4), so stockholder approval was not required. The Compensation Committee administers the plan, sets vesting and other terms, and may adjust awards in connection with a change in control.
Elutia Inc. has regained full compliance with Nasdaq’s continued listing standards. Nasdaq notified the company that its market value of listed securities was at least $35 million for eleven consecutive business days from January 21, 2026 through February 4, 2026, restoring compliance with Listing Rule 5550(b)(2). A separate Nasdaq notice confirmed that Elutia met the minimum $1.00 bid price requirement for ten consecutive business days from February 13, 2026 through February 27, 2026 under Listing Rule 5550(a)(2). With both matters now closed, Elutia’s Class A common stock will continue trading on the Nasdaq Capital Market under the symbol ELUT.
Alyeska Investment Group and related parties filed an amended Schedule 13G reporting a 3.18% passive ownership stake in Elutia Inc. Class A common stock. They report beneficial ownership of 1,281,172 shares, consisting of 1,000,000 common shares and 281,172 PIPE shares.
The percentage is based on 42,784,848 Elutia common shares outstanding as referenced from a recent Form 10-Q. The filers certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Elutia.
Nantahala Capital Management and its principals report a sizable stake in Elutia Inc. As of December 31, 2025, they may be deemed to beneficially own 4,124,854 shares of Elutia’s Class A common stock, representing 9.99% of the outstanding class.
The position includes 939,907 shares that can be acquired within sixty days through warrant exercises. Nantahala, Wilmot B. Harkey, and Daniel Mack report shared voting and dispositive power over all 4,124,854 shares, with no sole voting or dispositive power. A Nantahala-advised fund, BLACKWELL PARTNERS LLC - SERIES A, has rights to dividends or sale proceeds on more than five percent of the shares reported.
The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Elutia, aside from activities solely in connection with a nomination under Rule 14a-11.